Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2016
At a glance
- Drugs Human papillomavirus vaccine (Primary) ; Montanide ISA-51
- Indications Anal cancer; Cervical cancer; Head and neck cancer; Human papillomavirus infections; Penile cancer
- Focus Therapeutic Use
- Acronyms VicOryx
- Sponsors Oryx GmbH & Co
- 07 Mar 2016 Results published in the Cancer
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Immunogenicity and tolerability results (n=20) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.